The abstract is read at the publisher; the summary is JClub's.
In 176 avapritinib-treated patients with advanced systemic mastocytosis, a ≥25% reduction in KIT D816V allele burden within 6 months predicts prolonged overall survival.
- Why it matters: Clinicians need better ways to forecast disease course and outcomes before and during KIT inhibitor therapy in AdvSM, where baseline and early treatment signals may guide strategy.
- What they did: This retrospective study analyzed clinical, morphologic, laboratory, and genetic predictors in 79 midostaurin- and 176 avapritinib-treated patients, using 3-tier risk models based on baseline SRSF2/ASXL1/EZH2 or SRSF2/RUNX1/SETBP1 mutation counts.
- The result: For avapritinib, early KIT D816V variant allele frequency response and normalization of serum albumin within 6 months were significant predictors of longer overall survival, improving outcome prediction during treatment.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.